Nano Ultrasound Contrast Agent for Synergistic Chemo-photothermal Therapy and Enhanced Immunotherapy Against Liver Cancer and Metastasis

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2023 May 10

PMID 37162268

Authors

Yijie Qiu

Zhihua Wu

Yanling Chen

Jinghan Liao

Qi Zhang

Quan Wang

Yi Duan

Ke Gong

Sheng Chen

Liting Wang

Peili Fan

Yourong Duan

Wenping Wang

Yi Dong

Affiliations

Soon will be listed here.

Abstract

Advanced liver cancer is the most fatal malignant cancer, and the clinical outcomes of treatment are not very satisfactory due to the complexity and heterogeneity of the tumor. Combination therapy can efficiently enhance tumor treatment by stimulating multiple pathways and regulating the tumor immune microenvironment. Nanodrug delivery systems have become attractive candidates for combined strategies for liver cancer treatment. This study reports a nano ultrasound contrast agent (arsenic trioxide (ATO)/PFH NPs@Au-cRGD) to integrate diagnosis and treatment for efficient ultrasound imaging and liver cancer therapy. This nanodrug delivery system promotes tumor-associated antigens release through ATO-induced ferroptosis and photothermal-induced immunogenic cell death, enhancing the synergistic effects of ATO and photothermal therapy in human Huh7 and mouse Hepa1-6 cells. This drug delivery system successfully activates the antitumor immune response and promotes macrophage M1 polarization in tumor microenvironment with low side effects in subcutaneous and orthotopic liver cancer. Furthermore, tumor metastasis is inhibited and long-term immunological memory is also established in orthotopic liver cancer when the nanodrug delivery system is combined with anti-programmed death-ligand 1 (PD-L1) immunotherapy. This safe nanodrug delivery system can enhance antitumor therapy, inhibit lung metastasis, and achieve visual assessment of therapeutic efficacy, providing substantial potential in clinic applications for liver cancer.

Citing Articles

Knowledge structure and dynamic evolution of nanomedicine in liver cancer research: a scientometric analysis and visualization.

Li S, Cui D, Shao B, Kang Z, Yan G Front Pharmacol. 2025; 16:1509259.

PMID: 40078283 PMC: 11897278. DOI: 10.3389/fphar.2025.1509259.

Research Progress on Contrast-Enhanced Ultrasound (CEUS) Assisted Diagnosis and Treatment in Liver-Related Diseases.

Ying X, Dong S, Zhao Y, Chen Z, Jiang J, Shi H Int J Med Sci. 2025; 22(5):1092-1108.

PMID: 40027182 PMC: 11866529. DOI: 10.7150/ijms.101789.

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

Ultrasound-mediated nanomaterials for the treatment of inflammatory diseases.

Zhang K, Wang T, Huang X, Wu P, Shen L, Yang Y Ultrason Sonochem. 2025; 114:107270.

PMID: 39961217 PMC: 11875835. DOI: 10.1016/j.ultsonch.2025.107270.

Current status and future prospects of molecular imaging in targeting the tumor immune microenvironment.

Wang X, Shen W, Yao L, Li C, You H, Guo D Front Immunol. 2025; 16:1518555.

PMID: 39911388 PMC: 11794535. DOI: 10.3389/fimmu.2025.1518555.

References

Shortencarier M, Dayton P, Bloch S, Schumann P, Matsunaga T, Ferrara K . A method for radiation-force localized drug delivery using gas-filled lipospheres. IEEE Trans Ultrason Ferroelectr Freq Control. 2004; 51(7):822-31. DOI: 10.1109/tuffc.2004.1320741. View

Yu Z, Wang Y, Xu D, Zhu L, Hu M, Liu Q . G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma. Int J Nanomedicine. 2020; 15:81-95. PMC: 6956713. DOI: 10.2147/IJN.S230879. View

Singh B, Jang Y, Maharjan S, Kim H, Lee A, Kim S . Combination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer. Biomaterials. 2016; 116:130-144. DOI: 10.1016/j.biomaterials.2016.11.040. View

Li H, Zhang Y, Shu H, Lv W, Su C, Nie F . Highlights in ultrasound-targeted microbubble destruction-mediated gene/drug delivery strategy for treatment of malignancies. Int J Pharm. 2021; 613:121412. DOI: 10.1016/j.ijpharm.2021.121412. View

Hoos A . Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016; 15(4):235-47. DOI: 10.1038/nrd.2015.35. View

Jiang Q, Wang K, Zhang X, Ouyang B, Liu H, Pang Z . Platelet Membrane-Camouflaged Magnetic Nanoparticles for Ferroptosis-Enhanced Cancer Immunotherapy. Small. 2020; 16(22):e2001704. DOI: 10.1002/smll.202001704. View

Zhou F, Feng B, Yu H, Wang D, Wang T, Ma Y . Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade. Adv Mater. 2019; 31(14):e1805888. DOI: 10.1002/adma.201805888. View

Ren X . Cancer immunology and immunotherapy. Cancer Biol Med. 2022; 18(4). PMC: 8610153. DOI: 10.20892/j.issn.2095-3941.2021.0036. View

Yu X, Dai Y, Zhao Y, Qi S, Liu L, Lu L . Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat Commun. 2020; 11(1):1110. PMC: 7048802. DOI: 10.1038/s41467-020-14906-9. View

10.

Lim Y, Park O, Jung H . Gold nanolayer-encapsulated silica particles synthesized by surface seeding and shell growing method: near infrared responsive materials. J Colloid Interface Sci. 2003; 263(2):449-53. DOI: 10.1016/s0021-9797(03)00322-9. View

11.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

12.

Liu Y, Bhattarai P, Dai Z, Chen X . Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2018; 48(7):2053-2108. PMC: 6437026. DOI: 10.1039/c8cs00618k. View

13.

Liang C, Zhang X, Yang M, Dong X . Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater. 2019; 31(51):e1904197. DOI: 10.1002/adma.201904197. View

14.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

15.

He H, Du L, Guo H, An Y, Lu L, Chen Y . Redox Responsive Metal Organic Framework Nanoparticles Induces Ferroptosis for Cancer Therapy. Small. 2020; 16(33):e2001251. DOI: 10.1002/smll.202001251. View

16.

Kinowaki Y, Kurata M, Ishibashi S, Ikeda M, Tatsuzawa A, Yamamoto M . Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab Invest. 2018; 98(5):609-619. DOI: 10.1038/s41374-017-0008-1. View

17.

Hauff P, Seemann S, Reszka R, Schultze-Mosgau M, Reinhardt M, Buzasi T . Evaluation of gas-filled microparticles and sonoporation as gene delivery system: feasibility study in rodent tumor models. Radiology. 2005; 236(2):572-8. DOI: 10.1148/radiol.2362040870. View

18.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

19.

Fei W, Zhang Y, Han S, Tao J, Zheng H, Wei Y . RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. Int J Pharm. 2017; 519(1-2):250-262. DOI: 10.1016/j.ijpharm.2017.01.031. View

20.

Stockwell B, Jiang X, Gu W . Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol. 2020; 30(6):478-490. PMC: 7230071. DOI: 10.1016/j.tcb.2020.02.009. View